Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | LCT | P09848 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | UGCG | Q16739 | 2/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925026 | 0.81 | DDB1 (0.52) | DDB1CRBNMAOAMAOBOPRM1 | |
| SCHEMBL20485056 | 0.75 | TSHR (0.42) | MAPK1 | |
| SCHEMBL5213250 | 0.74 | MAOA (0.42) | DDB1CRBNMAOAMAOBOPRM1 | |
| SCHEMBL19277423 | 0.74 | DDB1 (0.55) | DDB1CRBNMAOAMAOBOPRM1 | |
| SCHEMBL30288394 | 0.74 | DDB1 (0.55) | DDB1CRBNMAOAMAOBOPRM1 | |
| SCHEMBL5443011 | 0.72 | AKR1B1 (0.43) | DDB1CRBNMAOAMAOBOPRM1 | |
| SCHEMBL926629 | 0.72 | MAOA (0.34) | DDB1CRBNMAOAMAOBVCP | |
| SCHEMBL2566062 | 0.72 | HTR6 (0.54) | MAOAMAOBOPRM1OPRK1KCNH2 | |
| SCHEMBL19890876 | 0.71 | MAOA (0.55) | DDB1CRBNMAOAMAOBMAPK1 | |
| SCHEMBL2566058 | 0.71 | PRMT6 (0.44) | DDB1CRBNMAOAMAOBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | DDB1 4695/4885CRBN 4183/4885MAOA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.